Perrigo (NYSE:PRGO) has been assigned a $107.00 target price by Cantor Fitzgerald in a report issued on Friday. The brokerage presently has a “buy” rating on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 17.48% from the company’s current price.
Several other research firms have also recently issued reports on PRGO. Jefferies Group set a $71.00 price objective on Perrigo and gave the stock a “hold” rating in a report on Sunday, October 29th. Argus upgraded Perrigo from a “hold” rating to a “buy” rating and set a $93.00 target price on the stock in a report on Friday, December 8th. UBS Group reiterated a “buy” rating and issued a $98.00 target price (up previously from $84.00) on shares of Perrigo in a report on Thursday, October 5th. Oppenheimer initiated coverage on Perrigo in a report on Thursday, September 7th. They issued an “outperform” rating and a $88.00 target price on the stock. Finally, Canaccord Genuity set a $100.00 target price on Perrigo and gave the company a “buy” rating in a report on Monday. One analyst has rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $92.00.
Perrigo (NYSE:PRGO) traded up $1.64 during midday trading on Friday, reaching $91.08. The company had a trading volume of 1,597,900 shares, compared to its average volume of 1,088,033. Perrigo has a 12-month low of $63.68 and a 12-month high of $92.04. The stock has a market cap of $12,596.79, a P/E ratio of -9.94, a P/E/G ratio of 1.73 and a beta of 0.70. The company has a quick ratio of 1.24, a current ratio of 1.72 and a debt-to-equity ratio of 0.54.
In other news, VP Todd W. Kingma sold 1,500 shares of the business’s stock in a transaction that occurred on Friday, December 28th. The stock was sold at an average price of $88.52, for a total transaction of $132,780.00. Following the completion of the transaction, the vice president now directly owns 19,565 shares in the company, valued at $1,731,893.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP John Wesolowski sold 388 shares of the business’s stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $87.20, for a total value of $33,833.60. Following the transaction, the executive vice president now owns 248 shares of the company’s stock, valued at $21,625.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 4,051 shares of company stock valued at $355,370. 6.90% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Perrigo by 2.1% during the second quarter. Vanguard Group Inc. now owns 14,874,096 shares of the company’s stock worth $1,123,292,000 after purchasing an additional 299,328 shares in the last quarter. State Street Corp raised its position in Perrigo by 1.7% in the second quarter. State Street Corp now owns 6,757,086 shares of the company’s stock worth $510,294,000 after purchasing an additional 112,287 shares in the last quarter. Greenlight Capital Inc. grew its stake in Perrigo by 14.8% during the third quarter. Greenlight Capital Inc. now owns 2,901,032 shares of the company’s stock worth $245,572,000 after buying an additional 374,032 shares during the last quarter. Parnassus Investments CA grew its stake in Perrigo by 7.1% during the third quarter. Parnassus Investments CA now owns 2,257,000 shares of the company’s stock worth $191,055,000 after buying an additional 150,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Perrigo by 18.2% during the second quarter. Goldman Sachs Group Inc. now owns 1,975,965 shares of the company’s stock worth $149,224,000 after buying an additional 304,950 shares during the last quarter. Institutional investors and hedge funds own 83.29% of the company’s stock.
WARNING: This article was originally published by American Banking and Market News and is owned by of American Banking and Market News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/05/perrigo-prgo-given-a-107-00-price-target-by-cantor-fitzgerald-analysts.html.
About Perrigo
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
